dc.creator | Đunić, Irena | |
dc.creator | Dopsaj, Violeta | |
dc.creator | Lesić, A. | |
dc.creator | Miljić, Predrag | |
dc.creator | Suvajdžić-Vuković, Nada | |
dc.creator | Tomin, Dragica | |
dc.creator | Novković, Aleksandra | |
dc.creator | Elezović, I | |
dc.date.accessioned | 2019-09-02T11:33:35Z | |
dc.date.available | 2019-09-02T11:33:35Z | |
dc.date.issued | 2013 | |
dc.identifier.issn | 1538-7933 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/1890 | |
dc.description.abstract | Background: Haemophilic arthropathy, with characteristic joint dam-
age, is the main cause of morbidity in individuals with severe haemo-
philia A. The most important clinical strategy for management of
these patients is treatment by continous prophylaxis with intrave-
nously applied factor (F) VIII. Recently, it was shown that serum and/
or urine biomarkers of cartilage turnover in joints reflected the degree
of total joint degradation in haemophilia patients.
Aims: The aims of this study were to detect correlations between serum
and urine concentrations of biomarkers of joint cartilage degradation
and the radiological score for haemophilic arthropathy, as well as to
estimate whether measurement of these biomarkers could be useful in
monitoring the efficacy of different (secondary) prophylaxis regimens
for severe haemophilia A.
Methods: This single-center study included 20 adult males with severe
haemophilia A manifested by plasma FVIII < 1% of normal, without
inhibitor. The first group involved five patients treated with full-dose
prophylaxis: 20 U/kg three times per week. The second group included
five patients given intermediate-dose prophylaxis: 10–15 U/kg three
times per week. The third group consisted of 10 patients treated on
demand (i.e. only in acute bleeding episodes). The following joint carti-
lage degradation products were measured: serum cartilage oligomeric
matrix protein (COMP) and urinary C-terminal telopeptide of type II
collagen (CTX-II). Blood and urine samples were collected initially,
before the start of treatment (marked as COMP-1 and CTX-II-1) and
after 3 months follow-up (marked as COMP-2 and CTX-II-2). Radio-
logical evaluation of haemophilic arthropathy was estimated initially
according to the Pettersson score. Approval from the local Ethics
Committee and informed written consent were obtained from each
subject.
Results: The mean age of the patients was 32 years (range 19–55). The
results showed significant positive correlations between the number of
points in the Pettersson score and both COMP level (r = 0.602,
P = 0.006) and CTX-II level (r = 0.580, P = 0.009). In the group of
patients given full-dose prophylaxis, the mean value for COMP-2 was
significantly lower than that for COMP-1 (P = 0.043), while in the
group of patients receiving intermediate-dose prophylaxis and in those
treated on demand the mean values of COMP-2 were not significantly
changed when compared to those for COMP-1. Likewise, in the group
of patients treated with full-dose prophylaxis, the mean value for
CTX-II-2 was significantly lower than that for CTX-II-1 (P = 0.014).
Moreover, the mean value of CTX-II-2 was also significantly
decreased compared to that for CTX-II-1 (P = 0.028) in the group receiving intermediate-dose prophylaxis. The mean values of CTX-II
in the group of patients treated on demand showed no change.
Conclusions: Joint cartilage degradation products, such as the biomar-
kers: serum COMP and urinary CTX-II, can provide an estimation of
the amount of joint damage in patients with haemophilia A. Measure-
ment of serum/urinary biomarker levels is useful for monitoring the
efficacy of the applied doses of FVIII in different treatment
approaches towards these patients. | |
dc.publisher | Elsevier Inc | |
dc.rights | openAccess | |
dc.source | Journal of Thrombosis and Haemostasis | |
dc.title | The importance of biomarkers of joint damage in monitoring the efficacy of different prophylaxis regimens for severe haemophilia A | en |
dc.type | conferenceObject | |
dc.rights.license | ARR | |
dcterms.abstract | Ђунић, Ирена; Допсај, Виолета; Новковић, Aлександра; Елезовић, И; Лесић, A.; Томин, Драгица; Сувајджић-Вуковић, Нада; Миљић, Предраг; | |
dc.citation.volume | 11 | |
dc.citation.issue | Supplement 2 | |
dc.citation.spage | 459 | |
dc.citation.epage | 460 | |
dc.citation.other | 11: 459-460 | |
dc.citation.rank | M21 | |
dc.description.other | XXIV Congress of the International Society on Thrombosis and Haemostasis, July 2013 | |
dc.identifier.wos | 000331833602377 | |
dc.identifier.doi | 10.1111/jth.12284 | |
dc.identifier.fulltext | http://farfar.pharmacy.bg.ac.rs/bitstream/id/11527/The_importance_of_pub_2013.pdf | |
dc.identifier.rcub | https://hdl.handle.net/21.15107/rcub_farfar_1890 | |
dc.type.version | publishedVersion | |